Real-time insights. Smarter decisions. Better trades.
🔍 Search Stocks 14 day Free Trial
FISHER & PAYKEL HEALTHCARE CORPORATION LIMITED (FPH)ASX AI Signals has generated 4 signal for FPH during the last 90 days, indicating active trading activity and ongoing AI monitoring
Latest FPH Signals | |
| 05/07/2026 | BUY |
| 04/07/2026 | BUY |
| 27/05/2026 | BUY |
FPH Share Price | |
| Current Price | $32.740 |
| 52 Week High | $34.700 |
| 52 Week Low: | $26.670 |
| Trading at (% of 52 Week High) | 94.35% |
Fisher & Paykel Healthcare Corporation Limited (ASX: FPH) designs, manufactures, and markets medical devices and systems for respiratory care, acute care, and surgery. The company develops products such as humidification therapy, non-invasive ventilation, and patient monitoring devices used in hospitals and homes worldwide.
The Health Care Equipment & Services sector on the ASX includes companies that produce medical devices, equipment, and supplies, as well as those providing healthcare-related services. This sector covers a wide range of products such as surgical instruments, diagnostic machines, and health monitoring devices. It also includes businesses involved in healthcare management, medical laboratories, and support services. These companies play a key role in supporting hospitals, clinics, and other healthcare providers to improve patient care. The sector is influenced by factors like technological advances, regulatory changes, and demand for healthcare services.
FPH shows strong fundamentals and positive market sentiment, supported by steady revenue growth and innovation in healthcare technology. However, macroeconomic uncertainties and sector-specific regulatory risks temper the confidence slightly.
(Bloomberg) — After a week in which Asian stocks posted both their biggest-ever plunge and their largest one-day gain since 2008, investors in the region are working weekends, skipping sleep, interrupting business trips, poring over social media and focusing on short-term trades, alert to the fact t It is hard to get excited after looking at Fisher & Paykel Healthcare's (NZSE:FPH) recent performance, when its stock has declined 13% over the past three months. To decide if this trend could continue, we decided to look at its weak fundamentals as they shape the long-term market trends. Particular https://www.tipranks.com/news/the-fly/fisher-paykel-healthcare-initiated-with-an-equal-weight-at-morgan-stanley
Morgan Stanley analyst David Bailey initiated coverage of Fisher & Paykel Healthcare with an Equal Weight rating and NZ$36.30 price target A strong EPS outlook over the next three years i Key Insights
Significantly high institutional ownership implies Fisher & Paykel Healthcare's stock price is sensitive to their trading actions 46% of the business is held by the top 25 shareholders Using data from analyst forecasts alongside ownership research, one can better assess the future perf Fisher & Paykel Healthcare (NZSE:FPH) is currently experiencing a mix of growth opportunities and hurdles. Recent developments include a substantial 10% increase in operating revenue, driven by strong performance in the home care segment and successful product innovations, contrasted with a 56% declLatest FISHER & PAYKEL HEALTHCARE CORPORATION LIMITED(FPH) News
Punch drunk traders across Asia ready for another week of drama
Fisher & Paykel Healthcare Corporation Limited (NZSE:FPH) Stock's On A Decline: Are Poor Fundamentals The Cause?
Fisher & Paykel Healthcare initiated with an Equal Weight at Morgan Stanley
Fisher & Paykel Healthcare Corporation Limited's (NZSE:FPH) institutional investors lost 8.5% last week but have benefitted from longer-term gains
Fisher & Paykel Healthcare (NZSE:FPH) Faces Profit Challenges Despite Strong Revenue and Product Innovation
Get access to daily BUY & SELL signals, advanced AI analysis, watchlists and email alerts.
14 Day Free Trial • Cancel Anytime • Founders Price $15/month
Start My Free Trial